{"id":"calcipotriene-and-betamethasone-dipropionate-ointment","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation or burning at application site"},{"rate":null,"effect":"Skin atrophy (with prolonged use)"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Hypercalcemia (rare, with extensive application)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcipotriene acts as a vitamin D3 receptor agonist, promoting keratinocyte differentiation and reducing proliferation of skin cells characteristic of psoriasis. Betamethasone dipropionate is a Class I (super-potent) topical corticosteroid that suppresses local inflammatory cytokines and immune cell infiltration. The combination provides synergistic anti-inflammatory and anti-proliferative effects on psoriatic lesions.","oneSentence":"This combination ointment uses calcipotriene (a vitamin D analog) to normalize skin cell differentiation and betamethasone dipropionate (a potent corticosteroid) to reduce inflammation and immune activation in psoriatic plaques.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:08.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"},{"name":"Psoriatic dermatitis"}]},"trialDetails":[{"nctId":"NCT05919082","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2023-06-21","conditions":"Stable Plaque Psoriasis","enrollment":604},{"nctId":"NCT00875277","phase":"PHASE2","title":"A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-04","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT01422434","phase":"PHASE3","title":"LEO 90105 Ointment in Japanese Subjects With Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-07","conditions":"Psoriasis","enrollment":676},{"nctId":"NCT00845481","phase":"PHASE2","title":"A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-01","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT00817219","phase":"PHASE2","title":"Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-07","conditions":"Psoriasis Vulgaris","enrollment":33},{"nctId":"NCT03806790","phase":"PHASE3","title":"Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2019-01-24","conditions":"Psoriasis Vulgaris","enrollment":182},{"nctId":"NCT00670241","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-04","conditions":"Psoriasis Vulgaris","enrollment":458},{"nctId":"NCT02668692","phase":"PHASE3","title":"LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-02","conditions":"Psoriasis Vulgaris","enrollment":213},{"nctId":"NCT01536886","phase":"PHASE2","title":"LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Psoriasis Vulgaris","enrollment":376},{"nctId":"NCT01347255","phase":"PHASE2","title":"A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-05","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT00216892","phase":"PHASE4","title":"Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-04","conditions":"Psoriasis Vulgaris","enrollment":1032},{"nctId":"NCT01946386","phase":"PHASE1","title":"A Vasoconstriction Study With LEO 90100","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09","conditions":"Psoriasis Vulgaris","enrollment":35},{"nctId":"NCT00248456","phase":"PHASE4","title":"Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-10","conditions":"Psoriasis Vulgaris","enrollment":320},{"nctId":"NCT00279162","phase":"PHASE3","title":"Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2005-12","conditions":"Psoriasis","enrollment":160},{"nctId":"NCT02605057","phase":"PHASE1","title":"Dermatopharmacokinetic Trial of LEO 80185 Gel","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-11","conditions":"Psoriasis Vulgaris","enrollment":32},{"nctId":"NCT03476746","phase":"PHASE1","title":"Dermatopharmacokinetic Trial of LEO 90100 Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-03-20","conditions":"Healthy","enrollment":58},{"nctId":"NCT06327620","phase":"NA","title":"Treatment Of Oral Lichen Planus","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2022-01-15","conditions":"Lichen Planus","enrollment":15},{"nctId":"NCT06011083","phase":"NA","title":"Topical Calcipotriol /Betamethasone Ointment in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-08-01","conditions":"Psoriasis Vulgaris, Fractional CO2 Laser","enrollment":40},{"nctId":"NCT00437255","phase":"PHASE4","title":"Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-08","conditions":"Plaque Psoriasis","enrollment":122},{"nctId":"NCT03462927","phase":"PHASE2","title":"A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-02-08","conditions":"Psoriasis Vulgaris","enrollment":63},{"nctId":"NCT04071106","phase":"PHASE2, PHASE3","title":"Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2019-09-01","conditions":"Psoriasis","enrollment":50},{"nctId":"NCT00924950","phase":"PHASE4","title":"Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2009-06","conditions":"Plaque Psoriasis, Psoriasis Vulgaris","enrollment":35},{"nctId":"NCT03004339","phase":"PHASE1","title":"Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test","status":"COMPLETED","sponsor":"DFB Soria, LLC","startDate":"2016-08","conditions":"Plaque Psoriasis","enrollment":13},{"nctId":"NCT01707043","phase":"PHASE4","title":"Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2012-10","conditions":"Plaque Psoriasis","enrollment":20},{"nctId":"NCT03399526","phase":"PHASE1","title":"1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-11","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT02973776","phase":"PHASE1","title":"Vasoconstriction Trial With LEO 90100 Aerosol Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-12","conditions":"Psoriasis Vulgaris","enrollment":36},{"nctId":"NCT02940002","phase":"PHASE1","title":"BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-10-12","conditions":"Psoriasis","enrollment":23},{"nctId":"NCT02999776","phase":"PHASE1","title":"Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis","status":"UNKNOWN","sponsor":"Pantec Biosolutions AG","startDate":"2016-11","conditions":"Psoriatic Plaque","enrollment":30},{"nctId":"NCT02955576","phase":"NA","title":"Microneedle Patch for Psoriatic Plaques","status":"UNKNOWN","sponsor":"The Catholic University of Korea","startDate":"2016-09","conditions":"Psoriasis, Administration, Topical","enrollment":20},{"nctId":"NCT01233583","phase":"","title":"Regulatory T-cells in Psoriasis Patients as Targets for Therapy","status":"COMPLETED","sponsor":"University of Aberdeen","startDate":"2010-06","conditions":"Psoriasis","enrollment":38},{"nctId":"NCT01413477","phase":"NA","title":"Nickel Desensitization Using Topical Therapy","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2011-08","conditions":"Allergic Contact Dermatitis","enrollment":24},{"nctId":"NCT00574249","phase":"PHASE3","title":"Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-11","conditions":"Chronic Plaque Psoriasis","enrollment":730}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taclonex® Ointment","Enstilar"],"phase":"marketed","status":"active","brandName":"Calcipotriene and betamethasone dipropionate ointment","genericName":"Calcipotriene and betamethasone dipropionate ointment","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination ointment uses calcipotriene (a vitamin D analog) to normalize skin cell differentiation and betamethasone dipropionate (a potent corticosteroid) to reduce inflammation and immune activation in psoriatic plaques. Used for Plaque psoriasis, Psoriatic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}